Integra LifeSciences (IART) vs OrthoPediatrics (KIDS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OrthoPediatrics (KIDS) has outperformed Integra LifeSciences (IART) over the past year, gaining 77.8% versus a gain of 10.0%. Over five years, KIDS leads with a -45.4% price change compared with -79.6% for IART. Integra LifeSciences is the larger company by market cap ($1.03 billion vs $828.7 million), about 1.2 times the size, while OrthoPediatrics is growing revenue faster (+15.4% vs +1.5%).
OrthoPediatrics converts more of its revenue into profit, with a net margin of -16.8% versus -31.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IART | KIDS |
|---|---|---|
| Share price | $13.25 | $31.74 |
| Market cap | $1.03B | $828.75M |
| 1-day change | -2.21% | -2.37% |
| YTD return | +6.68% | +78.72% |
| 1-year return | +10.05% | +77.82% |
| 5-year return | -79.57% | -45.40% |
| P/E ratio (TTM) | 77.94 | — |
| Forward P/E | 5.59 | — |
| EPS (TTM) | $0.17 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.64B | $236.35M |
| Revenue growth (YoY) | +1.53% | +15.45% |
| Net income (latest FY) | $-516.47M | $-39.65M |
| Gross margin | 50.86% | 73.05% |
| Operating margin | -30.17% | -16.60% |
| Net margin | -31.58% | -16.78% |
| 52-week high | $20.49 | $34.53 |
| 52-week low | $8.70 | $14.42 |
| Distance from 52-week high | -35.33% | -8.08% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +18.26% | +6.74% |
| Average volume | 1.05M | 274.74K |
| Shares outstanding | 77.80M | 26.11M |
| Employees | 4,427 | 602 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KIDS has outperformed IART by 67.8 percentage points over the past year.
- OrthoPediatrics is more profitable, keeping -16.8 cents of every revenue dollar as net income versus -31.6 cents for Integra LifeSciences.
- OrthoPediatrics grew revenue faster in its latest fiscal year (+15.45% vs +1.53%).
About Integra LifeSciences
IART stock →Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Health Care · Medical/Dental Instruments · 4,427 employees
About OrthoPediatrics
KIDS stock →OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products.
Health Care · Medical/Dental Instruments · 602 employees
IART vs KIDS FAQ
Which is bigger, Integra LifeSciences or OrthoPediatrics?
Integra LifeSciences (IART) is larger, with a market capitalization of $1.03B compared with $828.75M for OrthoPediatrics (KIDS).
Which stock has performed better over the past year, IART or KIDS?
KIDS returned +77.82% over the past 12 months, compared with +10.05% for IART (price return, excluding dividends). Past performance does not predict future results.
Are Integra LifeSciences and OrthoPediatrics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.